Comparative efficacy of six programmed cell death Protein-1 inhibitors as first-line treatment for advanced non-small cell lung cancer: a multicenter retrospective cohort study

• DOI: 10.3389/fphar.2024.1390872
• Publication Date: 2024-05-21T04:59:30Z
• Authors: Siyuan Chen; Tao Li; Wenyu Yang; Ting Wang; Yuhui Qin; Zhijuan Du; Yanan Li; Pengfei Cui; Yi Hu; Zhefeng Liu
• Keywords: Pharmacology; 03 medical and health sciences; 0302 clinical medicine; comparison; efficacy; PD-1 inhibitors; Therapeutics. Pharmacology; RM1-950; long-term survival; non-small cell lung cancer

The purpose of this study was to assess the comparative efficacy six programmed cell death-1 inhibitors (nivolumab, pembrolizumab, sintilimab, tislelizumab, toripalimab, and camrelizumab) that have been used as first-line therapy for Chinese patients with advanced non-small lung cancer (NSCLC), which remains unclear. We determined differences in by observing patient survival data, goal informing future treatment options. Retrospective data analysis from June 2015 April 2023 included 913 across groups: nivolumab (123%, 13.5%), pembrolizumab (421%, 46.1%), sintilimab (239%, 26.1%), tislelizumab (64%, 7.0%), toripalimab (39%, 4.3%), camrelizumab (27%, 3.0%). median progression-free (PFS) each group 16.0, 16.1, 18.4, 16.9, 23.7, 12.8 months, overall (OS) 33.7, 36.1, 32.5, not reached, 30.9 46.0 months nivolumab, groups, respectively. While existed objective response rates among groups ( p < 0.05), there were no significant (all > 0.05) PFS or OS. findings suggest comparable these PD-1 NSCLC treatment, underscoring their collective suitability aiding decisions.